Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18854465 | 0.74 | MEN1 (0.52) | MEN1KMT2AALDH1A1HSD17B10MMP9 | |
| SCHEMBL9103643 | 0.74 | MEN1 (0.52) | MEN1KMT2ASLC22A12ALDH1A1HSD17B10 | |
| SCHEMBL6986894 | 0.71 | MEN1 (0.48) | MEN1KMT2AALDH1A1HSD17B10MMP9 | |
| SCHEMBL19899969 | 0.70 | MEN1 (0.52) | MEN1KMT2AMMP9MMP13 | |
| SCHEMBL28456600 | 0.70 | MEN1 (0.52) | MEN1KMT2AALDH1A1HSD17B10MMP9 | |
| SCHEMBL10667947 | 0.70 | MAPT (0.48) | MEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL8764230 | 0.69 | MEN1 (0.64) | MEN1KMT2AALDH1A1HSD17B10MMP9 | |
| SCHEMBL2026682 | 0.68 | MEN1 (0.52) | MEN1KMT2AMMP9MMP13 | |
| SCHEMBL11131559 | 0.67 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL12978347 | 0.67 | MEN1 (0.47) | MEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146041-B1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | SERVIER LAB (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-6420413-B2 | 1-(6-((DIMETHYLAMINO)METHYL)-1-METHYL-2,3,5,6-TETRAHYDRO-1H -CYCLOBUTA(F) INDOL-6-YL)CYCLOHEXANOL, FOR EXAMPLE; TREATING PSYCHOLOGICAL DISORDERS SUCH AS DEPRESSION, PANIC ATTACKS, PHOBIAS, DRUG ABUSE, AS WELL AS OBESITY AND BULEMIA | LES LABORATORIES SERVIER (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | LES LABORATOIRES SERVIER (FR) | 2002-02-14 | — | — | US | disclosed |
| EP-1146041-A1 | Derivatives of heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane and their use as inhibitors of the recapture of serotonine and of noradrenaline | ADIR ET COMPAGNIE (FR) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019380-A1 | Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds | HSD3B2, HSD3B1, NR1H3 | MEN1 2535/4885KMT2A 2843/4885SLC22A12 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.